论文部分内容阅读
目的:为了解介入治疗对进行期肝癌的临床疗效。方法:本文分析了我院55例肝癌经导管灌注化疗及栓塞治疗的临床资料,随访48例。结果:48例中存活时间半年以上者36例,占75％,1年以上者16例,占33.3％,1年半以上者3例,占6.3％。其中单纯灌注化疗6例,存活超过半年者仅5例。灌注化疗+碘油栓塞(二联)15例,存活超过半年者13例,超过1年者6例。灌注化疗+碘油+明胶海绵栓塞(三联)23例,存活超过半年者18例,超过1年者10例,超过1年半者3例。结论:本法治疗肝癌有较好疗效,二联和三联疗法存活时间显著高于单灌疗法。
Objective: To understand the clinical efficacy of interventional treatment for advanced liver cancer. Methods: This article analyzed the clinical data of transcatheter arterial chemoembolization and embolization in 55 cases of liver cancer in our hospital. Follow-up was 48 cases. RESULTS: Of the 48 cases, 36 cases had a survival time of more than half a year, accounting for 75%, 16 cases accounted for more than 1 year, accounting for 33.3%, 3 cases accounted for more than 1 year and a half, accounting for 6.3%. Among them, 6 cases were treated with simple perfusion chemotherapy, and only 5 cases survived more than half a year. Infusion chemotherapy plus lipiodol embolization (two) in 15 cases, survival in more than six months in 13 cases, more than 1 year in 6 cases. Infusion chemotherapy + lipiodol + gelatin sponge embolization (triple) in 23 cases, 18 cases survived more than half a year, 10 cases more than 1 year, 3 cases more than 1 year and a half. Conclusion: This method is effective in the treatment of liver cancer. The survival time of the second and triple therapy is significantly higher than that of the monotherapy.